Publications by authors named "B Chretien"

Acute arterial hypertension within the critical care context may necessitate the administration of intravenous antihypertensive agents. Nicardipine and urapidil are notable for their application in intensive care units. Nonetheless, dihydropyridine calcium channel inhibitors (DCCIs) such as nicardipine are implicated in the impairment of hypoxic pulmonary vasoconstriction, potentially disrupting oxygenation.

View Article and Find Full Text PDF

Objectives: Proton pump inhibitor (PPI) exposure can lead to hyponatraemia, which is a common cause of delirium. An association between PPI exposure and delirium without hyponatraemia has been suggested in the literature. We aimed to describe the association between reports of delirium and PPI exposure and to assess the association between PPI and delirium with and without hyponatraemia.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates whether ibrutinib-related atrial fibrillation (IRAF) is linked to the dosage of ibrutinib, and if IRAF cases should lead to dosage adjustments or discontinuation of the drug.
  • Researchers analyzed data from the World Health Organization's VigiBase® pharmacovigilance database, focusing on 1,162 IRAF cases and various dosing regimens of ibrutinib (ranging from 140 mg/day to over 560 mg/day).
  • Results indicated that there was no significant association between the reported IRAF cases and the dosage of ibrutinib (p=0.09), suggesting IRAF is not a dose-dependent adverse drug reaction.
View Article and Find Full Text PDF

Background: Psychoactive drugs frequently cause delirium adverse events in older adults. However, few data on the relationship between antidepressants and delirium are available. Here, we investigated the association between antidepressant prescription and pharmacovigilance reports of delirium in older adults.

View Article and Find Full Text PDF

Recent research suggests that fetal exposure to antidepressants (ADs) is significantly associated with fetal death, including stillbirth. However, there has been limited investigation into the timing of AD exposure during pregnancy, the specific effect of each drug, and the possibility of indication bias. To address these gaps in knowledge, we conducted a systematic review of literature and disproportionality analyses using the WHO Safety Database (VigiBase).

View Article and Find Full Text PDF